Coronavirus (COVID-19) resources

Pharmacological treatment for chronic central neuropathic pain in people with multiple sclerosis

To assess the absolute and comparative benefit and tolerability of pharmacological therapies for the treatment of central neuropathic pain syndromes in people with MS.

This is a protocol.

You may also be interested in:

Pharmacological agents as symptomatic treatment for memory disorder in people with multiple sclerosis
The effect of amantadine for the treatment of fatigue in people with multiple sclerosis
Treatment of seizures for patients with multiple sclerosis
The effect of anti-spasticity agents in people with multiple sclerosis
The use of different treatment for incoordination of limb movement (ataxia) or tremor in people with multiple sclerosis

Health topics:

Neurology > Multiple sclerosis > Pharmacological treatments by clinical presentation

Published:

30 April 2020

Authors:

James E, Young CA, Gibbons EL, Shueb A, Tur C

Primary Review Group:

Multiple Sclerosis and Rare Diseases of the CNS Group

See the full Review on

the Cochrane Library

Print
PDF
Citation
James E, Young CA, Gibbons EL, Shueb A, Tur C. Pharmacological treatment for chronic central neuropathic pain in people with multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2020, Issue 4. Art. No.: CD013599. DOI: 10.1002/14651858.CD013599.